The Journal of Clinical Endocrinology and Metabolism shows how analysis of 70 postmenopausal women for 20 weeks demonstarted the potential of lycopene to reduce breast cancer risk. In the stydy, for the first 10 weeks, the women were required to follow a tomato-rich diet. This involved consuming a minimum of 25 mg of lycopene each day. Lycopene is an antioxidant found in tomatoes and other fruits and vegetables. For the remaining 10 weeks, the women followed a soy-rich diet. This required them to consume at least 40 g of soy protein daily. All women were asked to refrain from eating any soy or tomato products 2 weeks prior to each diet.
Link – http://www.vanguardngr.com/2013/12/tomato-rich-diet-reduces-breastprostate-cancer-risk/
The prostate may become infected, resulting in a painful condition sometimes difficult to eradicate. Infections cause inflammation and swelling, resulting in partial or complete urinary obstruction, pain and fever. Because the fatty tissues of the prostate are poorly infused with blood, Antibiotics such as Cipro or Septra need to be continued for several weeks to eradicate the infection. Much like the glandular cells of the female breast, prostate cells, influenced by hormones, can become cancerous. At first these cancer cells stay put and replicate slowly, resulting in gradual enlargement of the tumour. Once the cancer mass reaches a certain size it can be detected by rectal exam.
View the original article with any media, see here http://chealth.canoe.ca/channel_section_details.asp?text_id=2114&channel_id=10&relation_id=3949
‘No reduction’ in deaths caused by aggressive prostate cancer
As compared to annual screening, it is expected that screening intervals of 2 years preserve the majority of the benefits and reduce over diagnosis and false positives. Routine PSA screening is not recommended in men over age 70 or any man with less than a 10-15 year life expectancy.” Another controversy in prostate cancer centers on the treatment choice between aggressive surgical removal or a more conservative watch-and-wait approach. Medical News Today published news in August 2013 that research ‘backed watchful waiting’ in prostate cancer. Here is a further pair of recent headlines in prostate cancer news: add your opinion Reader OpinionsMost recent opinions are shown first ‘No Reduction’ In Deaths Caused By Aggressive Prostate CancerPosted by cb on 27 Dec 2013 at 7:08 amTo quote the creator of the PSA test: To me, the biggest issue is that we need to recognize that we all get prostate cancer, but that the death rate is only 226 per 100,000 men over 65 years old. Any excuse you use to biopsy the prostate — and we’ve been using PSA as an excuse — you’re very likely to find cancer. Post a Reply Alert a Moderator Add Your Opinion On This ArticleJoin the discussuon Please note that we publish the name you give us, but we do not publish your email address. We will email you to let you know when your comment has been published but will not use it for any other purpose.
For the original source including any supplementary images or video, visit ‘No reduction’ in deaths caused by aggressive prostate cancer
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
Over the next 12 months, you will receive updated qualitative analysis every time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence. Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis. Methodology For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports. Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model. Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs).
To read the original version including any supplementary images or video, visit Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top